Department of Chemistry, University of Cambridge, UK.
Centre for Integrative Biology, Università degli Studi di Trento, Italy.
FEBS J. 2018 Oct;285(19):3604-3630. doi: 10.1111/febs.14409. Epub 2018 Mar 4.
The link between protein aggregation and neurodegenerative disease is well established. However, given the heterogeneity of species formed during the aggregation process, it is difficult to delineate details of the molecular events involved in generating pathological aggregates from those producing soluble monomers. As aberrant aggregates are possible pharmacological targets for the treatment of neurodegenerative diseases, the need to observe and characterise soluble oligomers has pushed traditional biophysical techniques to their limits, leading to the development of a plethora of new tools capable of detecting soluble oligomers with high precision and specificity. In this review, we discuss a range of modern biophysical techniques that have been developed to study protein aggregation, and give an overview of how they have been used to understand, in detail, the aberrant aggregation of amyloidogenic proteins associated with the two most common neurodegenerative disorders, Alzheimer's disease and Parkinson's disease.
蛋白质聚集与神经退行性疾病之间的联系已得到充分证实。然而,鉴于聚集过程中形成的物种具有异质性,因此很难从产生可溶性单体的过程中详细描述参与产生病理性聚集的分子事件。由于异常聚集可能是治疗神经退行性疾病的药理学靶点,因此需要观察和表征可溶性低聚物,这促使传统的生物物理技术达到了极限,从而开发出了大量能够高精度和特异性检测可溶性低聚物的新工具。在这篇综述中,我们讨论了一系列已开发用于研究蛋白质聚集的现代生物物理技术,并概述了它们如何被用于详细了解与两种最常见的神经退行性疾病(阿尔茨海默病和帕金森病)相关的淀粉样蛋白异常聚集。